Yong He1, Zhenjie Jiang2, Fengzhi Tong3, Mingwu Li4, Xingru Yin5, Shixin Hu5, Linlin Wang6. 1. Master, Department of Thoracic Surgery, 5th People's Hospital of Dalian, China. Conception of the study, interpretation of data, statistical analysis. 2. Master, Department of Thoracic Surgery, People's Hospital of Dalian, China. Acquisition of data, statistical analysis. 3. Master, Clinical Laboratory, People's Hospital of Dalian, China. Acquisition and interpretation of data. 4. Bachelor, Department of Thoracic Surgery, 5th People's Hospital of Dalian, China. Acquisition and interpretation of data. 5. Bachelor, Department of Thoracic Surgery, 5th People's Hospital of Dalian, China. Acquisition of data, statistical analysis. 6. Bachelor, Matron, Department of Thoracic Surgery, 5th People's Hospital of Dalian, China. Acquisition of data, statistical analysis.
Abstract
PURPOSE: : To evaluate the possibility of using peripheral-blood presurfactant protein B (Pro-SFTPB) for screening non-small cell lung cancer (NSCLC). METHODS: : A total of 873 healthy volunteers and 165 lung cancer patients hospitalized in the Fifth People's Hospital of Dalian were tested Pro-SFTPB once every half year from January 2014 to September 2015. The healthy volunteers were also conducted spiral computed tomography (CT) examination once every year. The data were then com-pared and statistically analyzed. RESULTS: : The positive expression rate of Pro-SFTPB in NSCLC was significantly higher than that in healthy volunteers, and significantly higher in lung adenocarcinoma than in squamous cell carcinoma; additionally, the expression rate was increased with the in-crease of smoking index, and the intergroup differences showed statistical signifi-cance (p≤0.05). The positive rate of newly diagnosed lung cancer was 29.55%, higher than healthy volunteers (22.34%), but there was no significant difference (p>0.05). CONCLUSION: : Pro-SFTPB is over expressed in non-small cell lung cancer, especially in lung adeno-carcinoma, but it can't be used as a clinical screening tool for lung cancer.
PURPOSE: : To evaluate the possibility of using peripheral-blood presurfactant protein B (Pro-SFTPB) for screening non-small cell lung cancer (NSCLC). METHODS: : A total of 873 healthy volunteers and 165 lung cancer patients hospitalized in the Fifth People's Hospital of Dalian were tested Pro-SFTPB once every half year from January 2014 to September 2015. The healthy volunteers were also conducted spiral computed tomography (CT) examination once every year. The data were then com-pared and statistically analyzed. RESULTS: : The positive expression rate of Pro-SFTPB in NSCLC was significantly higher than that in healthy volunteers, and significantly higher in lung adenocarcinoma than in squamous cell carcinoma; additionally, the expression rate was increased with the in-crease of smoking index, and the intergroup differences showed statistical signifi-cance (p≤0.05). The positive rate of newly diagnosed lung cancer was 29.55%, higher than healthy volunteers (22.34%), but there was no significant difference (p>0.05). CONCLUSION: : Pro-SFTPB is over expressed in non-small cell lung cancer, especially in lung adeno-carcinoma, but it can't be used as a clinical screening tool for lung cancer.
Authors: Yi Lao; John David; Amin Mirhadi; Natasha Lepore; Howard Sandler; Yalin Wang; Richard Tuli; Wensha Yang Journal: Phys Med Biol Date: 2018-11-07 Impact factor: 3.609
Authors: Juan Moreno-Rubio; Santiago Ponce; Rosa Álvarez; María Eugenia Olmedo; Sandra Falagan; Xabier Mielgo; Fátima Navarro; Patricia Cruz; Luis Cabezón-Gutiérrez; Carlos Aguado; Gonzalo Colmenarejo; Marta Muñoz-Fernández de Leglaria; Ana Belén Enguita; María Cebollero; Amparo Benito; Isabel Alemany; Carolina Del Castillo; Ricardo Ramos; Ana Ramírez de Molina; Enrique Casado; Maria Sereno Journal: Cancer Biol Med Date: 2020-05-15 Impact factor: 4.248